|
Profile
|
Delegates :
KIYOSHI TAKAYAMA |
|
Incorporated :
July 7 , 2006 |
Paid in Capital :
59 Million yen |
Employees :
9 人 |
Address :
#110 W4-1-16, N21, KITA-KU, SAPPORO HOKKAIDO
〒0010021
|
TEL/FAX :
+81-11-708-7156 / +81-11-700-3009 |
URL:
http://www.nbhl.co.jp/ |
Attachment :
|
Mission/Background :
NBHL is committed to discovering First-In-Class medicines for the unmet medical needs with the sophisticated drug discovery platforms(Monoclonal Antibody for GPCR and Small compound screening ). We are looking for the pharmaceutical partners to develop our projects regarding lung inflammation and CNS. We also propose the technology alliance for functional mAbs targeting at GPCR, using our proprietary technology platform. |
Technology & Business
|
1.The antigen formats and the antibody screening methods fit the development of functional GPCR mAbs with the proprietary technologies. 2.The most crucial point of the platform is that the GPCR expressed in conformationally stable form in vivo is used as antigen, in stead of synthesized peptides corresponding to extracellular domain predicted in silico. 3.The platform have track records of success including GPCRs for lipid mediators, chemokines, a peptide and an amine. 4.Two of the functional GPCR mAbs are currently under development as therapeutic mAbs.
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Technology Platform for Functional Therapeutic GPCR mAbs
|
Discovery
|
Technology Platform fit the development of functional GPCR mAbs with the proprietary technolo
|
Conclusion of on-going partnership agreements
|
Small compounds for sleeping disorder with dementia
|
Discovery
|
The compounds, selective kinase inhibitor, augment NREM sleep.
|
CMC and Preclinical
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
1) Establishment of a research collaboration with major Japanese basic research laboratories 2) Minister of Economy, Trade and Industry (METI) supports our technology platform for functional mAbs targeting at GPCR financially.
|
Alliance strategy
|
1.NBHL produces humanized functional GPCR mAbs for pharmaceutical companies according to their specifications. 2.NBHL generates and optimizes the antibodies, whereas the partner is mainly responsible for pre-clinical and clinical development. 3.Development-dependent milestone payments and royalties on product sales are standard components of these agreements, whereas various options for alliance are available.
|
|
|